<DOC>
	<DOC>NCT01257061</DOC>
	<brief_summary>Atopic dermatitis is a recurrent pruritic skin disorder which has a significant morbidity and impaired quality of life due specially pruritus and physical visible skin lesions. The propose of this trial is evaluate the effectiveness of clemastine fumarate 1, 0 mg/g + dexamethasone 0, 5 mg/g compared to dexchlorpheniramine maleate 10 mg/g in eczema treatment.</brief_summary>
	<brief_title>Effectiveness of Clemastine Fumarate + Dexamethasone Compared to Dexchlorpheniramine Maleate in Eczema Treatment</brief_title>
	<detailed_description>Study design: â€¢ Double blinded, superiority, prospective parallel-group, intend to treat trial. Study design: - Experiment duration: 22 days - 2 visits (days 1,7,15 and 22) - Reducing Eczema Area and severity index evaluation - Adverse events evaluation</detailed_description>
	<mesh_term>Eczema</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Maleic acid</mesh_term>
	<mesh_term>Clemastine</mesh_term>
	<mesh_term>Chlorpheniramine</mesh_term>
	<mesh_term>Dexchlorpheniramine</mesh_term>
	<criteria>1. Patients must be able to understand the study procedures agree to participate and give written consent. 2. Patients with acute or subacute eczema. 3. Presence of symmetric lesions to compare on side to the other. 1. Pregnancy or risk of pregnancy. 2. Lactation 3. Use of antiinflammatory or immunosuppressive drugs (last 30 days prior to the study). 4. Sunlight over exposure in the last 15 days. 5. Any pathology or past medical condition that can interfere with this protocol.</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Dermatitis</keyword>
	<keyword>Dermatitis, Atopic</keyword>
</DOC>